Steven J.Corr (Steve)

Partner

Los Angeles + 1.213.243.2327 Irvine + 1.949.553.7518

Steve Corr is a technology and intellectual property trial lawyer with more than 16 years of litigation experience in trial courts and the USPTO and more than 8 years of business experience in the pharmaceutical and medical device industries. He has represented clients in IP matters as plaintiffs and defendants in diverse technology areas, including chemotherapy, invasive medical diagnostics, artificial heart valves, plastic surgery, pharmaceuticals, electronic online monitoring, audible consumer tracking, direct satellite broadcast television, flash memory, television technologies, and silicon chip production.

Steve has served as lead counsel for biotechnology and pharmaceutical companies, including multiple Hatch-Waxman matters for cancer therapy pharmaceuticals. Prior to practicing law, he developed extensive experience in the pharmaceutical and medical device industries, having held management positions for various technology-based health care companies. He regularly leverages this market experience in current representations.

Steve also served as lead counsel in a patent infringement matter for the Nielsen Company in the Eastern District of Texas, where, after Markman and summary judgment motions, the case was settled. He also recently served as lead counsel for a logistics corporation, winning summary judgment of noninfringement.

Steve has represented DIRECTV as lead day-to-day counsel for various patent matters, winning summary judgment of noninfringement in his latest matter.

Steve publishes and speaks in the U.S. on a variety of IP litigation topics. He serves as a member of various IP associations, including the Federal Circuit Bar Association, IPO, AIPLA, American Bar Association (Intellectual Property Law Section), Judge Michel Inn of Court, and the LAIPLA.

Experience

  • SKPI defeats Kaneka in patent infringement action regarding polyimide filmsJones Day obtained a summary judgment win on behalf of Korean-based SKC Kolon PI, Inc. ("SKPI"), which is principally engaged in the manufacture and distribution of polyimide films.
  • Celgene asserts its REVLIMID® patents against Apotex Inc. under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Apotex Inc. in a Hatch-Waxman litigation matter involving Apotex’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene asserts its REVLIMID® patents against Sun Pharma under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Sun Pharma Global FZE, Sun Pharma Global Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited in a Hatch-Waxman litigation matter involving Sun’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene enforces its REVLIMID® patents against Lotus Pharmaceutical under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Lotus Pharmaceutical Co., Ltd. in Hatch-Waxman litigations involving proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene asserts its REVLIMID® patents against Cipla under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Cipla Limited in Hatch-Waxman litigation matters involving Cipla’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene asserts its REVLIMID® patents against Dr. Reddy’s Laboratories under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Dr. Reddy's Laboratories in several Hatch-Waxman litigation matters involving DRL's proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene prevails in Apotex and Cipla IPR challenges of Abraxane® patentsJones Day served as lead counsel and successfully defended Celgene Corporation in connection with six inter partes review (IPR) petitions filed by Apotex or Cipla against U.S. Patent Nos. 8,138,229, 7,820,788, and 7,923,536, which are related to formulations for Celgene's chemotherapeutic drug marketed as Abraxane®.
  • Cree defends against patent infringement claims involving its LED packaging technology, contests validity of patents-in-suitJones Day represents Cree, Inc. in a patent infringement suit brought by Document Security Systems, Inc. in the Central District of California concerning four patents, which generally involve LED packaging technology.
  • Celgene enforces its Revlimid® patents against Zydus Pharmaceuticals under Hatch-Waxman ActJones Day is representing Celgene Corporation in a patent litigation against Zydus Pharmaceuticals and Cadila Healthcare over Revlimid®, Celgene's blockbuster drug for treating multiple myeloma and other cancers.
  • DIRECTV and component manufacturers prevail on summary judgment in patent infringement caseJones Day representing The DIRECTV Group, Inc., as well as numerous manufacturers of components used in DIRECTV's systems, prevailed by obtaining summary judgment rulings holding: (1) that a covenant not to sue between DIRECTV and Global was breached by Global's filing of this lawsuit; and (2) that the component manufacturers did not infringe Global's patents.
  • Ridge defends against competitor's allegations of infringementJones Day is defending Ridge Corporation against allegations that the company infringes five patents directed to aerodynamic drag reducing devices used in the trucking industry.
  • The Nielsen Company obtains preliminary injunctionJones Day obtained a preliminary injunction for The Nielsen Company (US), LLC, NeuroFocus, Inc., and TNC (US) Holdings, Inc. (collectively "The Nielsen Company") against the former chief executive officer of a Nielsen entity.
  • Board of Trustees of Univ. of Illinois settles patent infringement dispute involving generic version of Prezista®Jones Day represented the Board of Trustees of the University of Illinois in consolidated patent infringement actions against Mylan Pharmaceuticals Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., and Teva Pharmaceuticals USA, Inc., relating to the defendants' submission of Abbreviated New Drug Applications to the FDA seeking approval of generic versions of Prezista® (darunavir), a market-leading protease inhibitor.
  • DIRECTV defeats patent infringement charges over broadcast satellite TVJones Day defended DIRECTV and related companies in a patent infringement action involving multiple patents allegedly reading on aspects of its television satellite broadcast technology.
  • The Nielsen Company obtains settlement in patent infringement claim related to online measurement systems technologyJones Day reached a settlement for The Nielsen Company in a patent infringement action brought in the U.S. District Court for the Eastern District of Virginia against its competitor, comScore, Inc
  • Visa prevails in patent infringement action brought by SmartMetricJones Day obtained a stipulated judgment in favor of patent infringement defendant Visa Inc. following successful motions to dismiss, pre-Markman stay of discovery, and a favorable Markman order.
  • DIRECTV dismissed from patent infringement claims by Ganas relating to internet communication systemJones Day served as lead counsel for defendants DIRECTV and SAS Institute in a patent infringement action related to a system for communicating over the internet and through a firewall utilizing SOAP protocol.
  • DIRECTV wins patent appeal affirming its invalidity victory on summary judgmentJones Day successfully represented The DIRECTV Group, Inc. in a patent infringement action and appeal involving direct broadcast satellite television.
  • Dr. Pepper Snapple Group defends against patent infringement action brought by GeoTagJones Day is representing defendant Dr. Pepper Snapple Group in a patent infringement action related to an internet organizer for accessing geographically and topically based information.
  • Beckman Coulter defends against patent infringement action related to computer sales systemsJones Day represented Beckman Coulter, Inc. in a patent infringement action related to computerized sales systems. The case settled.
  • Speaking Engagements

    • January 30, 2020
      Ethical Updates in the IP Practice—Witness Testimony, Technology, and Potential Pitfalls
    • January 31, 2019
      Navigating Ethical Issues in the Intellectual Property Practice: Potential Ethical IP Perils and How to Get in Front of the Issues
    • November 9, 2018,
      Moderator - SoCalBio: 2nd Annual Digital Health Conference - Southern California Wearable Device Showcase III
    • April 25, 2018
      Biocom LA: Intellectual Property Pitfalls, Protecting Your Company After First Invention Disclosures & Patent Applications
    • January 31, 2018
      Ethics and the Intellectual Property Practice: Updates and Discussions Related to Tribunals, Potential Conflicts, and Client Concerns
    • January 25, 2017
      Ethics and the Intellectual Property Practice: Common Concerns Related to Duties to Clients, Tribunals, and Potential Conflicts
    • January 24, 2017
      Ethics and the Intellectual Property Practice: Common Concerns Related to Duties to Clients, Tribunals, and Potential Conflicts
    • January 27, 2016
      Alternative Approaches to Patent Disputes: Invalidity Strategies and Attacks at the United States Patent and Trademark Office
    • January 22, 2015
      Importation and Patent Infringement
    • January 22, 2014
      Document Preservation for Patent Litigation: The Proper Path in Light of the Federal Circuit’s Views
    • January 24, 2013
      Leahy-Smith America Invents Act: Updates Regarding Litigation Strategies and Impact of New Procedures
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.